By Lexaria Bioscience Corp. on Tuesday, 27 November 2018
Category: Pharmaceutical - BioTech

Lexaria Bioscience seeks Health Canada application for cannabinoid research lab in British Columbia

viewLexaria Bioscience Corp.

Separately, the company has appointed Dr Ed Ergenzinger as chief legal officer and senior vice president of innovation

Lexaria says the lab will enhance its ability to formulate for analytical purposes various products that may contain cannabinoids or other controlled substances

Cannabinoid-focused . () (OTCMKTS:LXRP) has applied for a Health Canada license to operate a research and development lab at the new headquarters the company is building in Kelowna, British Columbia.

Lexaria said in a press release Monday that the lab will enhance its ability to formulate for analytical purposes various products that may contain cannabinoids or other controlled substances.

READ: Lexaria Bioscience creates four new subsidiaries

The company added that it expects to work on cannabinoid-related formulations as soon as the lab receives its research license. Experimental work on nicotine formulations, non-steroidal anti-inflammatory drugs, vitamins and other bioactive compounds will begin soon after completion of lab construction. The company expects to occupy the new headquarters and lab by the end of January 2019.

Separately, the company said it has appointed Dr Ed Ergenzinger as chief legal officer and senior vice president of innovation. Ergenzinger is a US-licensed patent attorney who also holds a doctorate in neuroscience with concentrations in pharmacology and physiology.

Shares of Lexaria slipped C$0.21 to C$1.35 in Tuesday’s Canadian trading. They were down US$0.16 to US$1.03 on the OTC market.

Contact Dennis Fitzgerald at [email protected]

CSE:LXX

Market: CSE
Market Cap: $52.47 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

1 week, 5 days ago

2 min read

Related Posts